Pancreatic β Cell CHOP Inhibition for PDAC and ER Stress Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Type 2 diabetes (T2DM) is a risk factor for pancreatic ductal adenocarcinoma (PDAC), and there is currently no effective treatment for PDAC, which is one of the most lethal human solid tumors.
Innovation Solution
Inhibiting CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) in pancreatic β cells using a CHOP inhibiting moiety and a pancreatic β cell targeting moiety, such as a nucleic acid or peptide, to regulate CHOP expression and alleviate ER stress, thereby treating pancreatic cancer and associated conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CHOP is inhibited in pancreatic β cells, then glycemic control is improved and insulin secretion is normalized, but this may affect pancreatic cell function and cancer treatment efficacy
Solution Approach 1:
The patent applies local quality by using a pancreatic β cell targeting moiety that directs the CHOP inhibiting moiety specifically to pancreatic β cells. This ensures that CHOP inhibition occurs only in the desired cell type, improving glycemic control while minimizing off-target effects on other pancreatic cells and maintaining overall pancreatic function.
Solution Approach 2:
The patent uses a pancreatic β cell targeting moiety as an intermediary that mediates the delivery of the CHOP inhibiting moiety to the correct cell type. This intermediary ensures selective delivery and inhibition, allowing therapeutic effect in β cells while preserving function in other cells.
2Object-affected harmful factors
If CHOP is inhibited selectively in pancreatic β cells, then pancreatic cancer growth and metastasis are prevented, but this requires highly specific targeting to avoid off-target effects
Solution Approach 1:
The patent employs local quality by designing a composition where the CHOP inhibiting moiety is coupled with a pancreatic β cell targeting moiety. This ensures that the anti-cancer effect is localized specifically to pancreatic β cells, preventing cancer growth and metastasis while avoiding off-target effects on other tissues through highly specific cellular targeting.
Solution Approach 2:
The pancreatic β cell targeting moiety serves as an intermediary that enables selective delivery of the CHOP inhibiting moiety to pancreatic β cells. This intermediary component provides the necessary specificity to target cancer-prone cells while sparing normal cells, resolving the complexity of achieving selective inhibition.
3Reliability
If a CHOP inhibiting moiety with pancreatic β cell targeting is administered, then ER stress is alleviated and insulin secretion is normalized, but this requires precise delivery to the correct cell type
Solution Approach 1:
The patent uses a pancreatic β cell targeting moiety as an intermediary to achieve precise delivery of the CHOP inhibiting moiety to pancreatic β cells. This intermediary ensures that ER stress alleviation and normalization of insulin secretion occur specifically in the target cells, providing reliable therapeutic effect while managing delivery precision requirements.
Solution Approach 2:
The composition design implements local quality by concentrating the CHOP inhibiting activity specifically in pancreatic β cells through the targeting moiety. This localized action ensures reliable ER stress alleviation and insulin secretion normalization in the correct cell type without requiring complex systemic delivery mechanisms.
Data Source
AI summary
Methods and compositions related to treating pancreatic cancer are described.